Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11357992 | 0.73 | GABRA1 (0.38) | GABRA1GABRB2 | |
| SCHEMBL394894 | 0.72 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL285281 | 0.68 | GABRA1 (0.54) | GABRA1GABRB2 | |
| SCHEMBL21211716 | 0.68 | POLB (0.38) | GABRA1GABRB2 | |
| SCHEMBL29636322 | 0.68 | GABRA1 (0.54) | GABRA1GABRB2 | |
| SCHEMBL5352813 | 0.68 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL5354591 | 0.68 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL20780625 | 0.68 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL5354598 | 0.68 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL5352817 | 0.68 | GABRA1 (0.34) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645914-B2 | Method for the telomerization of non-cyclic olefins | EVONIK OXENO GMBH (DE) | 2010-01-12 | — | — | US | disclosed |
| US-20070213574-A1 | METHOD FOR THE TELOMERIZATION OF NON-CYCLIC OLEFINS | EVONIK DEGUSSA GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213574-A1 | METHOD FOR THE TELOMERIZATION OF NON-CYCLIC OLEFINS | TELO2, PCNA, TERT | GABRA1 4648/4885GABRB2 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.